A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with impaired renal function and participants on hemodialysis.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Incyte Corporation Call Center (US)
- 전화번호: 1.855.463.3463
- 이메일: medinfo@incyte.com
연구 연락처 백업
- 이름: Incyte Corporation Call Center (ex-US)
- 전화번호: +800 00027423
- 이메일: eumedinfo@incyte.com
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Ability to comprehend and willingness to sign a written ICF for the study.
-
Aged 18 to 85 years, inclusive, at the time of signing the ICF.
-
Severe renal impairment or ESRD based on CKD-EPI (National Kidney Foundation).
• Participants with impaired renal function should have stable renal function (ie, those with acute changes in renal function should not be enrolled in the study).
-
Medical findings consistent with the degree of renal dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory determinations at screening or check-in (as applicable). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible.
-
BMI of 18.0 to 43.0 kg/m2 (inclusive) at screening.
-
Ability to swallow and retain oral tablets.
-
Willingness to avoid pregnancy, breastfeeding, or fathering children.
Exclusion Criteria:
-
History of uncontrolled or unstable cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, or neurological disease within 6 months before screening.
- History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including but not limited to the following:
- Recent myocardial infarction (within 6 months before check-in).
- New York Heart Association Class III or IV congestive heart failure.
- Unstable angina (within 6 months before check-in).
- Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker).
- Uncontrolled hypertension.
-
Participants who have a current, functioning organ transplant or are on the national transplant list and expected to receive a transplant within 3 months.
-
History of an autoimmune disease diagnosis (eg, myasthenia gravis).
-
History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg at screening, confirmed by repeat testing).
-
Participants who have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
-
Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).
-
History of malignancy within 5 years before screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
-
Current or recent (within 3 months before screening) clinically significant GI disease or surgery (including cholecystectomy [< 2 months]; excluding appendectomy and hernia repair) that could affect the absorption of study drug.
-
Confirmed resting pulse rate (up to 2 consecutive measurements) < 40 bpm or > 100 bpm at screening.
-
Participants with laboratory values outside the accepted range for participants with severe renal impairment or ESRD at screening.
-
Any major surgery within 4 weeks before screening. Note: This does not include procedure for HD.
-
Blood transfusion within 4 weeks before check-in (Day -1).
-
Chronic or current active infectious disease (including latent tuberculosis) requiring systemic antibiotic, antifungal, or antiviral treatment.
-
Positive test result for HBV, HCV, or HIV. Upon testing, HBV DNA and HCV RNA must be undetectable.
- Note 1: Participants with no prior history of HBV infection who have been vaccinated against HBV and who have a positive HBsAg antibody test as the only evidence of prior exposure may participate in the study.
- Note 2: Participants who have cleared a prior HBV infection (defined as HbsAg negative, HBsAb positive, or HBcAb positive) may be included at the discretion of the investigator.
-
Receipt of any vaccine including but not limited to live (including attenuated), influenza, and SARS-CoV-2 vaccines within 3 months before the first dose of study drug.
-
Medical or self-reported history of alcoholism within 3 years before screening.
-
History of significant alcohol use, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females, within 3 months before screening.
-
Treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another investigational medication or current enrollment in another investigational drug study.
-
Treatment within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database Program for prohibited drugs).
-
Active infection requiring systemic therapy.
-
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
-
Known hypersensitivity or severe reaction to INCB161734, any excipients of INCB161734, or any KRAS inhibitors (refer to the IB).
-
Inability to undergo venipuncture or tolerate venous access, or inadequate veins for repeat venipuncture or venous access as determined by the investigator.
-
Tobacco or nicotine-containing product use of > 10 cigarettes per day within 1 month before screening.
-
Use of prescription drugs (including hormonal contraceptives) within 14 days before study drug administration or nonprescription medications/products (including megadose vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations as well as pre/probiotics) within 7 days of study drug administration
- Note 1: Occasional acetaminophen, standard-dose ibuprofen, and standard-dose vitamins are permitted.
- Note 2: Established therapy for renal disease, or the treatment of associated disorders, that has been stable for at least 7 days prior to study drug administration, is allowed if approved by the medical monitor and investigator.
-
Participants who are pregnant or lactating.
-
Excessive exercise (eg, Ironman, bi/triathlon) within 3 months before screening.
-
Participants who had a change in disease status within 30 days before screening, as documented by the participant's medical history, that is deemed clinically significant by the investigator.
-
Participants who have a history of paracentesis within 3 months prior to check-in.
-
Participants who required new medication or an increase in dose for renal disease within 3 months prior to check-in.
-
Participants who have a history of unstable diabetes mellitus (as evidenced by hemoglobin A1c ≥ 10.0%). Medications for treatment of diabetes mellitus must be reviewed and approved by the investigator and medical monitor.
-
Esophageal banding within 3 months prior to check-in or required any other treatment for GI bleeding within 6 months prior to check-in.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Group 1: Severe renal impairment
Participants with severe renal impairment will be enrolled in Group 1. |
single dose administered orally |
|
실험적: Group 2: End-stage renal disease (ESRD)
Participants with end-stage renal disease will be enrolled in Group 2. |
single dose administered orally |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PK for plasma INCB161734: Cmax
기간: Up to approximately 3.5 months
|
Defined as the maximum plasma concentration. |
Up to approximately 3.5 months
|
|
PK for plasma INCB161734: AUClast
기간: Up to approximately 3.5 months
|
Defined as the area under the concentration-time curve from time zero to time of the last quantifiable concentration. |
Up to approximately 3.5 months
|
|
PK for plasma INCB161734: AUCinf
기간: Up to approximately 3.5 months
|
Defined as the area under concentration-time curve from time zero extrapolated to infinity. |
Up to approximately 3.5 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Treatment-Emergent Adverse Events (TEAEs)
기간: Up to approximately 3.5 months and 30 days
|
Adverse events reported for the first time or worsening of a pre-existing event, occurring after first dose of study drug. |
Up to approximately 3.5 months and 30 days
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Incyte Medical Monitor, Incyte Corporation
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- INCB161734-106
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .